Tekmira Pharmaceuticals Corp.
Tekmira Pharmaceuticals Corp. is a biopharmaceutical company, which focuses on advancing novel ribonucleic acid interference therapeutics and providing its lipid nanoparticle delivery technology to pharmaceutical partners. It is focused on developing and advancing novel RNA interference therapeutics, as well as pursuing partnering opportunities for its leading lipid nanoparticle (LNP) delivery technology. The company's products include TKM-PLK1, TKM-HBV, TKM-ALDH2 and TKM-Ebola and TKM-Marburg. Tekmira Pharmaceuticals was founded in 1992 and is headquartered in Burnaby, Canada.